Blood Disorders & Hematology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

This phase 3 trial compares two types of stem cell transplants for young patients with acute leukemia or myelodysplastic syndrome. It looks at whether using a donor who is a close family member but not a perfect match is better or worse than using a perfectly matched donor from outside the family. The findings may expand transplant options and help families make more informed decisions about treatment.

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With High-Risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

This completed phase 3 study tested blinatumomab, an antibody therapy, against standard chemotherapy in children facing a high-risk return of acute lymphoblastic leukemia. The trial’s results could offer a treatment that improves survival chances while potentially causing fewer severe side effects. Families and doctors now have more information to consider for managing this challenging stage of the disease.

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

This ongoing phase 3 trial is exploring a new combination of treatments for older adults newly diagnosed with diffuse large B-cell lymphoma. Adding the drug acalabrutinib to a gentler chemotherapy regimen may improve how long patients live without the cancer worsening. Those affected by this aggressive lymphoma may benefit from new therapy options emerging from this study.

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

This international phase 3 trial is testing new chemotherapy and antibody treatment combinations for children with acute myeloid leukemia. The goal is to find safer treatments that still work well, improving survival and reducing harmful side effects. Results from this study will help guide future care for children with this serious blood cancer.

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease

This phase 3 trial is investigating a gene therapy called CTX001 for children with severe sickle cell disease who have not responded well to standard medication. If successful, this therapy could reduce painful episodes and improve quality of life for these young patients. The study includes sites in several countries, reflecting global interest in new sickle cell treatments.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.